Free Newsletter
Gates Foundation helps launch $1.5B program
A group of five nations has joined the Bill & Melinda Gates Foundation to offer advance guarantees for new vaccines that can guard against some of the most common diseases seen in developing countries. Collectively, they are investing $1.5 billion with the expectation that the lure of new funds will spur manufacturers to develop new and better vaccines.
One of the first goals will be to develop vaccines for pneumococcal diseases which kill about 1.6 million people--mostly children--every year. Vaccine manufacturers in the program will be required to offer vaccines at a reduced rate once the program's money is spent. Britain, Italy, Canada, Russia, Norway and the Bill and Melinda Gates Foundation will work with the WHO, UNICEF and the World Bank on the Advance Market Commitment program.
"It is novel. This hasn't been done before," said Canada's finance minister, Jim Flaherty. "This innovative new model will mean faster access to vaccines for millions of children in poor countries," said Bill Gates.
- read the report from Pharmacy Europe
- check out the story from the Montreal Gazette
Related Articles:
Gates uses mosquitoes to spread his malaria message
Gates to increase spending despite heavy losses
Donors pledge $635M to eradicate polio
Gates galvanizes anti-malaria campaign
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: